You are here

AACR

J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows

J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows

Fierce Pharma

Bristol Myers Squibb

Multiple Myeloma

Flag link:

Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting

Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting

BioSpace

Bridge Biotherapeutics

non-small cell lung cancer

Flag link:

AACR 2023 – Hippo makes a splash

AACR 2023 – Hippo makes a splash

EP Vantage

Vivace Therapeutics

Flag link:

AACR: Lilly challenges Amgen, Mirati with early KRAS data, heading for a field 'much less crowded than it seems'

AACR: Lilly challenges Amgen, Mirati with early KRAS data, heading for a field 'much less crowded than it seems'

Fierce Biotech

Mirati Therapeutics

KRAS inhibitors

Flag link:

REGN5459 Delivers Dose-Dependent Responses in Relapsed/Refractory Myeloma

REGN5459 Delivers Dose-Dependent Responses in Relapsed/Refractory Myeloma

Onc Live

relapsed or refractory multiple myeloma

Flag link:

Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination

Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination

BioSpace

Flag link:

AACR: Patient deaths taint Roche's industry-first early-stage liver cancer readout for Tecentriq and Avastin

AACR: Patient deaths taint Roche's industry-first early-stage liver cancer readout for Tecentriq and Avastin

Fierce Pharma

Flag link:

AACR: AstraZeneca offers first look at Imfinzi's resectable lung cancer showing, fueling a key debate

AACR: AstraZeneca offers first look at Imfinzi's resectable lung cancer showing, fueling a key debate

Fierce Pharma

non-small cell lung cancer

Flag link:

AACR 2023 – Moderna's immunotherapeutic splash

AACR 2023 – Moderna's immunotherapeutic splash

EP Vantage

Moderna Therapeutics

Relay Therapeutics

Vivace Therapeutics

Flag link:

AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark

AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark

Fierce Biotech

Flag link:

Novartis Highlights Early Data from Potential Lumakras Competitor at AACR

Novartis Highlights Early Data from Potential Lumakras Competitor at AACR

BioSpace

clinical trials

Flag link:

AACR 2022 – A weekend of updates yields few winners

AACR 2022 – A weekend of updates yields few winners

EP Vantage

Bicycle Therapeutics

Rubius Therapeutics

C4 Therapeutics

Flag link:

BrickBio Debuts Powerful Advantage of Novel ADCs, Protein Origami, and Synthetic Virology at 2022 AACR

BrickBio Debuts Powerful Advantage of Novel ADCs, Protein Origami, and Synthetic Virology at 2022 AACR

BioSpace

antibody-drug conjugate

protein origami

Flag link:

Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data

Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data

Marketwatch

Bicycle Therapeutics

clinical trials

urothelial cancer

Flag link:

AACR 2022 – Affimed shows that 2021 was no fluke

AACR 2022 – Affimed shows that 2021 was no fluke

EP Vantage

natural killer cells

Flag link:

AACR22: As post-Covid development takes shape, BioNTech reports first human data for CAR-T/cancer vaccine combo

AACR22: As post-Covid development takes shape, BioNTech reports first human data for CAR-T/cancer vaccine combo

Endpoints

clinical trials

testicular cancer

Flag link:

AACR: 2 years in, Amgen fortifies Lumakras lung cancer data fortress for upcoming Mirati, Novartis KRAS battle

AACR: 2 years in, Amgen fortifies Lumakras lung cancer data fortress for upcoming Mirati, Novartis KRAS battle

Fierce Pharma

Mirati Therapeutics

Flag link:

AACR Preview: AstraZeneca to Showcase "Oncology Revolution"

AACR Preview: AstraZeneca to Showcase "Oncology Revolution"

BioSpace

Flag link:

At a Recent Cancer Research Conference, Instil Bio Stole the Show

At a Recent Cancer Research Conference, Instil Bio Stole the Show

Motley Fool

Flag link:

AACR attendees told about tactics to tackle loss of T cell function in CAR T cell treatment

AACR attendees told about tactics to tackle loss of T cell function in CAR T cell treatment

Biopharma Reporter

Memorial Sloan Kettering

Flag link:

Pages